ZURICH: Roche has received European Commission approval for its Tecentriq drug in combination with Avastin and chemotherapy as an initial treatment for people with a specific type of lung cancer, the Swiss pharma company said on Friday.
The combination has been approved as a first-line treatment for people with metastatic non-squamous non-small cell lung cancer .NSCLC is the most common type of lung cancer, accounting for about 85 percent of all cases, Roche said.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: